An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
Atara Biotherapeutics to Participate in Cell Therapy Panel Discussion at the Citigroup 17th Annual Biopharma Conference
Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary
Atara Biotherapeutics (NASDAQ: ATRA) announced participation by CEO Pascal Touchon in a cell therapy panel at the Citigroup 17th Annual Biopharma Conference on September 7, 2022, at 6:40 a.m. PDT. The event will be accessible via a live webcast on the company's website, with an archived version available for 30 days post-event. Atara specializes in T-cell immunotherapy, focusing on EBV T-cell platforms to tackle cancer and autoimmune diseases. Their lead program is in Phase 3 development for EBV+ post-transplant lymphoproliferative disease.
Positive
None.
Negative
None.
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--
Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced that Pascal Touchon, President and Chief Executive Officer, will participate in a cell therapy panel discussion at the Citigroup 17th Annual Biopharma Conference on Wednesday, September 7, 2022 at 6:40 a.m. PDT / 9:40 a.m. EDT.
A live webcast of the presentation will be available by visiting the Investor Events and Presentations section of atarabio.com. An archived replay of the webcast will be available on the Company's website for 30 days following the live presentation.
About Atara Biotherapeutics, Inc.
Atara Biotherapeutics, Inc. (@Atarabio) is a pioneer in T-cell immunotherapy leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for patients with serious diseases including solid tumors, hematologic cancers and autoimmune disease. With our lead program in Phase 3 clinical development and currently under review to support registration in Europe, Atara is the most advanced allogeneic T-cell immunotherapy company and intends to rapidly deliver off-the-shelf treatments to patients with high unmet medical need. Our platform leverages the unique biology of EBV T cells and has the capability to treat a wide range of EBV-associated diseases, or other serious diseases through incorporation of engineered CARs (chimeric antigen receptors) or TCRs (T-cell receptors). Atara is applying this one platform, which does not require TCR or HLA gene editing, to create a robust pipeline including: tab-cel® (tabelecleucel) in Phase 3 development for Epstein-Barr virus-driven post-transplant lymphoproliferative disease (EBV+ PTLD); ATA188, a T-cell immunotherapy targeting EBV antigens as a potential treatment for multiple sclerosis; and multiple next-generation chimeric antigen receptor T-cell (CAR-T) immunotherapies for both solid tumors and hematologic malignancies. Improving patients’ lives is our mission and we will never stop working to bring transformative therapies to those in need. Atara is headquartered in South San Francisco. For additional information about the company, please visit atarabio.com and follow us on Twitter and LinkedIn.
When is Atara Biotherapeutics participating in the Citigroup 17th Annual Biopharma Conference?
Atara Biotherapeutics will participate in the Citigroup 17th Annual Biopharma Conference on September 7, 2022, at 6:40 a.m. PDT.
Who from Atara Biotherapeutics will speak at the Citigroup event?
Pascal Touchon, President and CEO of Atara Biotherapeutics, will speak at the Citigroup event.
Where can I find the live webcast of Atara Biotherapeutics' presentation?
The live webcast of Atara Biotherapeutics' presentation can be found on their Investor Events and Presentations webpage.
What is Atara Biotherapeutics' main focus in biopharmaceuticals?
Atara Biotherapeutics focuses on T-cell immunotherapy, particularly using its allogeneic EBV T-cell platform for cancer and autoimmune disease treatments.
What is the current development status of Atara Biotherapeutics' lead program?
Atara's lead program is in Phase 3 development for Epstein-Barr virus-driven post-transplant lymphoproliferative disease (EBV+ PTLD).
